Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331719 · ClinicalTrials.gov registry record
Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 16
- Enrollment target
NCT02331719 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants.
The verdict
NCT02331719 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
Intracerebral hemorrhage (ICH) is the most severe form of stroke: early mortality is 40%, and 80%-of survivors are physically disabled with high rates of cognitive impairment and depression. In an effort to address the issues with conventional treatments, a new integrated systematic approach has been developed. This approach utilizes an educational process where specific core competencies (pillars) of mapping, navigation, access, optics and automated resection have been integrated into a single standardized system to deliver targeted therapy for an individual patient based on location and patient factors. This system has demonstrated safety and efficacy in oncology patients and is also FDA approved for use in the ICH patient population as well. This registry will collect data form multiple site that preform the MiSPACE procedure as part of clinical care. The intent of this registry is to collect data on the economic impact as well as clinical outcomes using the MiSPACE approach with the integrated technology in the early treatment of ICH.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02331719
The ClinicalTrials.gov registry entry for NCT02331719 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02331719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02331719 about?
NCT02331719 is a clinical study titled "Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation". Intracerebral hemorrhage (ICH) is the most severe form of stroke: early mortality is 40%, and 80%-of survivors are physically disabled with high rates of cognitive impairment and depression. In an effort to address the issues with conventional treatments, a new integrated systematic approach has be...
What is the current status of trial NCT02331719?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2017-10.
Who is sponsoring clinical trial NCT02331719?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.